Roche, Prothena hus­tle to PhII with their dis­ease-mod­i­fy­ing Parkin­son's drug tar­get­ing al­pha-synu­cle­in

Prothena turned up at the big Alzheimer’s/Parkin­son’s con­fer­ence in Vi­en­na over the week­end to de­tail ear­ly-stage da­ta show­ing how its Roche-part­nered drug PRX002/RG7935 can flush …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER